Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 5201–5250 of 18642
On May 22, 2024, the Board appointed Mr. Kowieski, age 47, as Chief Financial Officer ("CFO") of Evoke Pharma, Inc. (the "Company") effective May 22, 2024.
On May 28, 2024, the Company also announced the appointment, effective immediately, of Susan Landi as the Company’s new Chief Financial Officer and Treasurer.
On May 28, 2024, Farmland Partners Inc. (the “Company”) announced that the Company and James Gilligan, the Company’s Chief Financial Officer and Treasurer, mutually agreed to separate.
On May 28, 2024, the Board of Directors appointed Thomas Schuetz, MD, PhD, then-current President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, and as Principal Executive Officer, Principal Financial and Principal Accounting Officer of the Company, effective immediately.
On May 28, 2024, Vered Bisker-Leib, PhD, MBA, resigned as Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) and resigned as a member of the Board of Directors, of Compass Therapeutics, Inc. (the “Company”) effective the same date.
Effective as of the Initial Term Date, the Board appointed Mr. Thomas Langan as Interim Chief Executive Officer of the Company, and the Board reduced the size of the Board from seven directors to six directors.
On May 27, 2024, the Company entered into an extension letter agreement (the “Extension Agreement”) with Mr. Westerfield to extend his appointment through December 31, 2024.
Kevin C. Gorman, Ph.D. will retire as Neurocrine’s President and Chief Executive Officer effective as of October 11, 2024 (the “Transition Date”).
appointment of Kyle Gano, Ph.D., age 51, to serve as Neurocrine’s President and Chief Executive Officer, effective as of the Transition Date.
As of May 24, 2024, the Company terminated all of its employees and executive officers, including Chief Executive Officer and Co-Founder Clint Sever, Chief Business Officer Chris Achar and Chief Accounting Officer Randall Pollard.
On May 28, 2024, Aviat Networks, Inc. (the “Company”) announced the appointment of Michael Connaway as the Company’s Senior Vice President and Chief Financial Officer.
Dr. Han-Wen Ou was appointed as Chief Executive Officer, Chief Financial Officer, Secretary and sole Director.
On May 22, 2024, Cactus, Inc. (the “Company”) appointed Jay Nutt as the Company’s Executive Vice President, Chief Financial Officer and Treasurer, with an anticipated start date of June 3, 2024.
Mr. Nutt will replace Alan Keifer, who has been serving as the Company’s Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.
Effective May 9, 2024, Mina Kim was appointed as the Chief Executive Officer of the Company
By mutual agreement of Shao-Lee Lin, M.D., Ph.D. and the Company, Dr. Lin stepped down from her position as Chief Executive Officer and as a member of the Board, effective on May 8, 2024.
it is expected that Mr. Shoukry will be appointed chief executive officer of the Company.
appointed Senior Vice President and Chief Accounting Officer Jonathan W. (“Butch”) Oorlog, Jr., age 60, as Chief Financial Officer, effective October 1, 2024
On May 22, 2024, the Company and Steven Kopjo entered into an Employment Agreement
On May 20, 2024, the Board of Directors (the “Board”) of Definitive Healthcare Corp. (the “Company”) appointed Kevin Coop to the position of Chief Executive Officer (“CEO”) and as a member of the Board, each effective June 24, 2024 (the “Start Date”).
Effective on the Start Date, Jason Krantz, the Company’s founder, Executive Chairman of the Board and current Interim CEO will step down from his role as Interim CEO and continue to serve as Executive Chairman of the Board.
On May 24, 2024, Collegium Pharmaceutical, Inc. (the “Company”) entered into a letter agreement (the “Letter Agreement”) with Michael Heffernan in connection with Mr. Heffernan’s appointment as Interim President and Chief Executive Officer of the Company.
Also on May 24, 2024, the Company entered into a Separation and Release Agreement with Mr. Ciaffoni (the “Separation Agreement”) in connection with his previously announced departure from the Company.
Dr. Rao Mulpuri (Chief Executive Officer)
Effective May 24, 2024 (the “Effective Date”), Christopher Harms is no longer serving as Chief Financial Officer and principal financial and accounting officer of Amplitude, Inc. (the “Company”).
the board of directors of the Company (the “ Board ”) approved on May 16, 2024 the separation of the Company’s Chief Executive Officer, Abigail Jenkins, effective as of the Effective Date.
Effective June 30, 2024, after a career spanning more than 35 years, Kim R. Tsuchimoto, the Chief Financial Officer of Monopar Therapeutics Inc. (“Monopar” or the “Company”), will be retiring.
On May 23, 2024, the Company’s Board of Directors appointed, Karthik Radhakrishnan, age 53, to succeed Ms. Tsuchimoto as Monopar’s Chief Financial Officer, principal accounting officer and principal financial officer effective July 1, 2024.
As previously announced on April 15, 2024, Jeffrey R. Tarr, the former President and Chief Executive Officer of Skillsoft Corp. (the “Company”), retired from his position effective as of April 16, 2024 (the “Transition Date”).
Also on May 23, 2024, Jeffrey S. Ervin notified the Board of his resignation as Chief Executive Officer and director, effective immediately.
On May 23, 2024, the Company appointed Faith Zaslavsky as Chief Executive Officer of the Company, effective immediately.
The Board approved the appointment of Lance Rosenzweig to serve as Interim CEO of the Company, effective May 22, 2024.
The employment of Jason Dies as Interim Chief Executive Officer of Pitney Bowes Inc. (the “Company”) ended effective May 21, 2024.
On May 22, 2024, the Board of Directors of Sandy Spring Bancorp, Inc. (the “Company”) appointed Charles S. Cullum, the Company’s current Deputy Chief Financial Officer and Treasurer, as Chief Financial Officer.
Philip J. Mantua, the Company’s current Chief Financial Officer, who previously announced his retirement, will continue with the Company until the end of the year to support this leadership transition.
The Company’s Board of Directors has appointed Scott Maskin as the Company’s Interim Chief Executive Officer , effective May 17, 2024.
On May 17, 2024, Kyle Udseth informed Pineapple Energy Inc. (the “Company”) of his decision to resign as Chief Executive Officer and as a director of the Company, effective May 17, 2024.
Effective on May 7, 2024 (the “Separation Date”), Jeffrey Rittichier departed as Chief Executive Officer and director of the Company.
appointed Peter Knag as the Company’s Chief Financial Officer, effective June 5, 2024
the Company announced Mr. Baker’s retirement and that its Board of Directors (the “Board”) appointed Catherine “Cassie” J. Boggs to serve as Interim President and Chief Executive Officer.
On May 22, 2024, Phillips S. Baker, Jr., the President and Chief Executive Officer and a director of Hecla Mining Company (the “Company”), informed the Company that he retired from his officer position and resigned his director position effective immediately
Mr. Yendall will depart the Company on June 7, 2024 and will be entitled to the severance payments set forth under the applicable provisions of his employment agreement.
On May 23, 2024, SiriusPoint Ltd. (the “ Company ”) announced the appointment of James J. McKinney as its new Chief Financial Officer effective June 3, 2024, to replace Steve Yendall.
Chris Lundell had stepped down as the Company’s Chief Executive Officer.
Douglas A. Starrett’s officer title was changed from “Chief Executive Officer and President” to “Chief Executive Officer,”
the Boards of NW Holdings and NW Natural designated Mr. Justin B. Palfreyman, President of NW Holdings and NW Natural, as successor to the office of CEO of NW Holdings and NW Natural, upon Mr. Anderson’s retirement.
David H. Anderson, Chief Executive Officer (CEO) of Northwest Natural Holding Company (NW Holdings) and Northwest Natural Gas Company (NW Natural) informed the Board at its May 23, 2024 meeting of his decision to retire from his position as CEO of NW Holdings and NW Natural effective April 1, 2025.
On May 17, 2024, Craig Snyder, the Chief Executive Officer and a member of the Board of Directors (the “Board”) of the Company, notified the Board that he will resign as Chief Executive Officer of the Company and as a member of the Board, effective as of May 27, 2024.
On May 23, 2024, the Board appointed Barbara Sher, the Company’s Chief Operating Officer, to the position of Chief Executive Officer, effective as of May 27, 2024.
The Board announced that it will appoint Joseph Ruzynski as Chief Executive Officer, effective July 1, 2024
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.